Explore CJC-1295 DAC 10mg vial labels, concentration and U-100 examples, human half-life evidence, material identity, and formulation-specific handling.
CJC-1295 DAC 10mg is a nominal 10 mg vial amount of an albumin-binding GHRH analog. The long half-life was measured in healthy humans, but neither that result nor the package size establishes a human dose. No source here establishes 10 mg as the largest standard format or the most purchased size.
What Is CJC-1295 DAC?
CJC-1295 is a synthetic GHRH analog, not an identical copy of the native hormone. The DAC modification enables albumin binding and changes the material’s pharmacological profile.
That albumin bond is the entire point of the modification. Unmodified GHRH clears from the body in minutes, while the DAC version stays measurable for days. A 10 mg vial arrives as a lyophilized powder, meaning the peptide was freeze-dried into a cake at the bottom of the glass. It is not a liquid and it is not a finished pharmaceutical product.
CJC-1295 DAC is not FDA-approved for human use in the United States.
CJC-1295 With DAC vs. CJC-1295 No DAC
The material marketed as CJC-1295 no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited human trials. FDA’s assessment cautions against transferring the DAC pharmacological profile to non-DAC forms; it does not establish a universal 30-minute human half-life or a daily regimen for all such products.
| Property | DAC compound | No-DAC material |
|---|---|---|
| Half-life | 5.8–8.1 days in healthy adults | Not established by the cited DAC trials |
| Albumin binding | Enabled by the DAC modification | Lacks that modification |
| GH pattern | Increased trough/mean GH with pulses preserved | No direct comparative safety advantage here |
| Schedule | Short controlled trial designs | No approved daily regimen supplied |
| Package size | Nominal quantity must be checked | Package size is not an exposure schedule |
Study material should be selected for the scientific question and validated method, not an unsupported contrast of continuous DAC release versus natural no-DAC pulses.
Reconstitution Math for a 10mg Vial
The following calculations assume the stated peptide mass is accurate, dissolution is complete, and the specified volume is the final solution volume. They illustrate laboratory concentration and aliquot arithmetic, not a recommended human amount. Added diluent is only an approximation to final volume, and vessel capacity must be checked. A 5 mg DAC vial example uses the same mass-versus-concentration distinction; a different vial size does not establish a different physiological requirement.
| Final volume for nominal 10 mg | Calculated concentration | Volume containing 100 mcg | U-100 markings for that volume |
|---|---|---|---|
| 1 mL | 10 mg/mL (10,000 mcg/mL) | 0.01 mL | 1 unit |
| 2 mL | 5 mg/mL (5,000 mcg/mL) | 0.02 mL | 2 units |
| 3 mL | 3.33 mg/mL (3,333 mcg/mL) | 0.03 mL | 3 units |
| 5 mL | 2 mg/mL (2,000 mcg/mL) | 0.05 mL | 5 units |
Use material-specific mixing and storage instructions. Neither ordinary agitation nor an arbitrary temperature excursion is shown here to destroy every batch; deviations need evaluation against supporting data.
On a U-100 scale, one unit marking represents 0.01 mL, but the smallest physical tick may represent more than one unit. Confirm graduations and device resolution before measuring a small aliquot.
Storage and Handling
- Storage temperature and use-by time depend on the peptide formulation, solvent, concentration, container, and validated stability data. There is no universal “refrigerate for four weeks” or “freeze at −20°C” rule for every retail CJC-1295 vial. CDC’s opened multidose-vial guidance is not evidence that a newly mixed peptide remains chemically stable for 28 days.
- Aliquot size and freeze-thaw limits depend on the exact formulation and validated assay procedure.
- An opened diluent date and a reconstituted peptide’s use-by date are separate questions.
- Shipping suitability depends on supported transport conditions; warm arrival alone cannot establish degradation without a relevant specification.
Legal Status and Safety
CJC-1295 has no FDA-approved human indication. A “research use only” label does not itself authorize human treatment or settle whether a particular sale, import, or possession is lawful. Product claims, intended use, compounding requirements, and jurisdiction matter; an ordinary retail research vial is not an approved prescription medicine.
The 2026 WADA Prohibited List includes CJC-1295 among GHRH analogs prohibited in and out of competition.
The short human studies reported injection-site reactions, flushing or warmth, headache, and gastrointestinal symptoms. FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data and impurity/immunogenicity concerns. Neither a tolerable first exposure nor a normal blood test establishes long-term safety.
Reading Community Discussions Critically
A thread needs its original date, product and lot, and supporting test records before a quality or dosing claim can be evaluated. No market-wide mislabeling rate is established here.
For a blend, verify each constituent’s amount rather than assuming the total label is an equal split. A DAC/other-peptide mixture also requires its own compatibility evidence.
A lot-matched report can document the sample tested, method, date, and result. It does not prove every vial has the same content, that a supplier-submitted sample was independently purchased, or that the material is sterile or clinically safe. Acceptance criteria should follow the laboratory’s intended assay, rather than a universal 98% purity threshold. Related research also covers CJC 1295 No DAC Ipamorelin Reddit: What Users Say.
Key Takeaways
- The cited human DAC half-life is prolonged, but a universal “300-fold longer than no DAC” claim requires a valid same-context comparison that is not supplied here.
- For laboratory calculations, verify peptide mass and final solution volume separately. A larger nominal vial does not alter the conversion formula or establish a larger appropriate exposure.
- CJC-1295 DAC is a research chemical, not an approved medicine, and it carries real legal and safety risk.
Frequently Asked Questions
What is a 10mg CJC-1295 DAC vial used for?
A nominal 10 mg vial is a package quantity for a specified research material. Early human DAC studies examined pharmacokinetics and GH/IGF-1 responses, but the label does not establish actual content, a human dose, or a validated bodybuilding application.
How much bacteriostatic water do I add to 10mg of CJC-1295 DAC?
A nominal 10 mg label does not dictate how much water to add. A verified 10 mg in a final 2 mL would be 5 mg/mL; in a final 5 mL it would be 2 mg/mL. These are laboratory calculations assuming accurate content and complete dissolution, not a validated solvent choice or dose recommendation.
Is CJC-1295 DAC the same as CJC-1295 without DAC?
The DAC compound carries an albumin-binding modification; no-DAC materials are distinct and need their own identity and clinical evidence. The cited human DAC studies do not establish a universal 30-minute no-DAC half-life, an approved daily regimen, or a comparative safety advantage.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.